Epstein-Barr virus nuclear antigen 2 and latent membrane protein independently transactivate p53 through induction of NF-κB activity

Journal of Virology

Volumn 70, Issue 7, 1996, Pages 4849-4853

  Chen, Weiping ^a   Cooper, Neil R ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN; PROTEIN P53;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL CYCLE; CELL DIVISION; EPSTEIN BARR VIRUS; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TRANSACTIVATION;

EID: 0030011643     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.7.4849-4853.1996     Document Type: Article

References (66)

1. Alfieri, C., M. Birkenbach, and E. Kieff. 1991. Early events in Epstein-Barr virus infection of human B lymphocytes. Virology 181:595-608.
2. Allday, M. J., D. H. Crawford, and B. E. Griffin. 1989. Epstein-Barr virus latent gene expression during the initiation of B cell immortalization. J. Gen. Virol. 70:1755-1764.
3. 2/M when it is transactivation defective. EMBO J. 14:4994-5005.
4. Allday, M. J., A. Sinclair, G. Parker, D. H. Crawford, and P. J. Farrell. 1995. Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53. EMBO J. 14:1382-1391.
5. Ballerini, P., G. Gaidano, J. Z. Gong, V. Tassi, G. Saglio, D. M. Knowles, and R. Dalla-Favera. 1993. Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Blood 81:166-176.
6. Berg, L. C., C. M. Copenhaver, V. A. Morrison, S. A. Gruber, D. L. Dunn, K. Gajl-Pecialska, and J. G. Strickler. 1992. B-cell lymphoprolifevative disorders in solid-organ transplant patients: detection of Epstein-Barr virus by in situ hybridization. Hum. Pathol. 23:1.59-163.
7. Cherney, B. W., and K. Bhatia. 1994. A role for deregulated c-myc expression in apoptosis of Epstein-Barr virus-immortalized B cells. Proc. Natl. Acad. Sci. USA 91:12967-12971.
8. Edwards, R. H., and N. Raab-Traub. 1994. Alterations of the p53 gene in Epstein-Barr virus-associated immunodeficiency-related lymphomas. J. Virol. 68:1309-1315.
9. Effert, P., R. McCoy, M. Abdel-Hamid, K. Flynn, Q. Zhang, P. Busson, T. Tursz, E. Liu, and N. Raab-Traub. 1992. Alterations of the p53 gene in nasopharyngeal carcinoma. J. Virol. 66:3768-3775.
10. El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
11. Fahraeus, R., H. Li Fu, I. Ernberg, J. Finke, M. Rowe, G. Klein, K. Falk, E. Nilsson, M. Yadav, P. Busson, T. Tursz, and B. Kallin. 1988. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int. J. Cancer 42:329-338.
12. Farrell, P. J., G. J. Allan, F. Shanahan, K. H. Vousden, and T. Crook. 1991. p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J. 10: 2879-2887.
13. Fearon, D. T., and R. H. Carter. 1995. The CD 19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu. Rev. Immunol. 13:127-149.
14. Gaidano, G., P. Ballerini, J. Z. Gong, G. Inghirami, A. Neri, E. W. Newcomb, I. T. Magrath, D. M. Knowles, and R. Dalla-Favera. 1991. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 88:5413-5417.
15. Gordon, J., L. Walker, G. Guy, G. Brown, M. Rowe, and A. Rickinson. 1986. Control of human B-lymphocyte replication. II. Transforming Epstein-Barr virus exploits three distinct viral signals to undermine three separate control points in B-cell growth. Immunology 58:591-595.
16. Gorman, C. M., L. F. Moffat, and B. H. Howard. 1982. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol. Cell. Biol. 2:1044-1051.
17. Green, S., I. Issemann, and E. Sheer. 1988. A versatile in vivo and in vitro cukaryotic expression vector for protein engineering. Nucleic Acids Res. 16:364.
18. Hammarskjöld, M.-L., and M. C. Simurda. 1992. Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-κB activity. J. Virol. 66:6496-6501.
19. Hennessy, K., and E. Kieff. 1985. A second nuclear protein is encoded by Epstein-Barr virus in latent infection. Science 227:1238.
20. Herrero, J. A., P. Mathew, and C. V. Paya. 1995. LMP-1 activates NF-κB by targeting the inhibitory molecule 1κBα. J. Virol. 69:2168-2174.
21. Ho, M., G. Miller, R. W. Atchison, M. K. Breinig, J. S. Dummer, W. Andiman, T. E. Starzl, R. Eastman, B. P. Griffith, R. L. Hardesty, H. T. Bahnson, T. R. Hakala, and J. T. Rosenthal. 1985. Epstein-Barr virus infections and DNA hybridization studies in posttransplant lymphoma and lymphoproliferative lesions: the role of primary infection. J. Infect. Dis. 152:876-886.
22. Hollyoake, M., A. Stühler, P. Farrell, J. Gordon, and A. Sinclair. 1995. The normal cell cycle activation program is exploited during the infection of quiescent B lymphocytes by Epstein-Barr virus. Cancer Res. 55:4784-4787.
23. Huen, D. S., S. A. Henderson, D. Croom-Carter, and M. Rowe. 1995. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-κB and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 10:549-560.
24. Hutt-Fletcher, L. M. 1987. Synergistic activation of cells by Epstein-Barr virus and B-cell growth factor. J. Virol. 61:774-781.
25. Karp, J. E., and S. Broder. 1991. Acquired immunodeficiency syndrome and non-Hodgkin's lymphomas. Cancer Res. 51:4743-4756.
26. 1-rcgulating proteins by Epstein-Barr virus mutants conditional for EBNA2. EMBO J. 14:88-96.
27. Klein, G. 1989. Viral latency and transformation: the strategy of Epstein-Barr virus. Cell 58:5-8.
28. Laherty, C. D., H. M. Hu, A. W. Opipari, F. Wang, and V. M. Dixit. 1992. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor κB. J. Biol. Chem. 267:24157- 24160.
29. Lane, D. P. 1992. p53. guardian of the genome. Nature (London) 358:15-16.
30. Lane, D. P., and L. V. Crawford. 1979. T antigen is bound to a host protein in SV40-transformed cells. Nature (London) 278:261-263.
31. Linzer, D. I. H., and A. J. Levine. 1979. Characterization of a 54,000 MW cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17:43-52.
32. Luxembourg, A. T., and N. R. Cooper. 1994. T cell dependent B cell activating properties of antibody-coated small latex heads: a new model for B cell activation. J. Immunol. 153:604-614.
33. Mann, K. P., D. Staunton, and D. A. Thorley-Lawson. 1985. Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells. J. Virol. 55:710-720.
34. Mitchell, T., and B. Sugden. 1995. Stimulation of NF-κB-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus. J. Virol. 69:2968-2976.
35. Mulligan, R. C., and P. Berg. 1981. Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase. Proc. Natl. Acad. Sci. USA 78:2072-2076.
36. Nakamura, H., J. W. Said, C. W. Miller, and H. P. Koeffler. 1993. Mutation and protein expression of p53 in acquired immunodeficiency syndrome-related lymphomas. Blood 82:920-926.
37. Nemerow, G. R., and N. R. Cooper. 1981. Isolation of Epstein-Barr virus and studies of its neutralization by human IgG and complement. J. Immunol. 127:272-278.
38. Nemerow, G. R., A. T. Luxembourg, and N. R. Cooper. 1994. CD21/CR2: its role in EBV infection and immune function. Epstein-Barr Rep. 1:59-64.
39. Oren, M. 1992. p53: the ultimate tumor suppressor gene? FASEB J. 6:3169-3176.
40. Pallesen, G., S. J. Hamilton-Dutoit, M. Rowe, and L. S. Young. 1991. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 337:320-322.
41. Palmero, I., A. Holder, A. J. Sinclair, C. Dickson, and G. Peters. 1993. Cyclins D1 and D2 are differentially expressed in human B-lymphoid cell lines. Oncogene 8:1049-1054.
42. Rooney, C., J. G. Howe, S. H. Speck, and G. Miller. 1989. Influences of Burkitt's lymphoma and primary B cells on latent gene expression by the nonimmortalizing P3J-HR-1 strain of Epstein-Barr virus. J. Virol. 63:1531-1539.
43. Rosen, C. A., J. G. Sodroski, and W. A. Haseltine. 1995. The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat. Cell 41:813-823.
44. Rowe, M., M. Peng-Pilon, D. S. Huen, R. Hardy, D. Croom-Carter, E. Lundgren, and A. B. Rickinson. 1994. Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-κB activation and to induction of cell surface markers. J. Virol. 68:5602-5612.
45. Said, J. W., R. Barrera, I. P. Shinaku, H. Nakamura, and H. P. Koeffler. 1992. Immunohistochemical analysis of p53 expression in malignant lymphomas. Am. J. Pathol. 141:1343-1348.
46. Sarnow, P., Y. S. Ho, J. Williams, and A. J. Levine. 1982. Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54kd cellular protein in transformed cells. Cell 28:387-394.
47. Scala, G., I. Quinto, M. R. Ruocco, M. Mallardo, C. Ambrosino, B. Squitieri, P. Tassone, and S. Venuta, 1993. Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1. J. Virol. 67:2853-2861.
48. Scheffner, M., B. A. Werness, J. M. Huibregtse, A. J. Levine, and P. M. Howley. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136.
49. Schreiber, E., P. Matthias, M. M. Müller, and W. Schaffner. 1989. Rapid detection of octamer binding proteins with "mini extracts", prepared from a small number of cells. Nucleic Acids Res. 17:6419.
50. 1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J. 13:3321-3328.
51. Su, I.-J., H.-C. Hsieh, K.-H. Lin, W.-C. Uen, C.-L. Kao, C.-J. Chen, A.-L. Cheng, M. E. Kadin, and J.-Y. Chen. 1991. Aggressive peripheral T-cell lymphomas containing Epstein-Barr viral DNA: a clinicopathologic and molecular analysis. Blood 77:799-808.
52. Sun, Y., G. Hegamyer, Y.-J. Cheng, and I.-H. Chen. 1992. An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Proc. Natl. Acad. Sci. USA 89:6516-6520.
53. Szekely, L., K. Pokrovskaja, W.-Q. Jiang, G. Selivanova, M. Löwbeer, N. Ringertz, K. G. Wiman, and G. Klein. 1995. Resting B-cells, EBV-infected B-blasts and established lymphoblastoid cell lines differ in their Rh, p53 and EBNA-5 expression patterns. Oncogene 10:1869-1874.
54. Szekely, L., G. Selivanova, K. P. Magnusson, G. Klein, and K. G. Wiman. 1993. EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc. Natl. Acad. Sci. USA 90:5455-5499.
55. Tanner, J., Y. Whang, J. Sample, A. Sears, and E. Kieff. 1988. Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes. J. Virol. 62:4452-4464.
56. Thomas, J. A., M. J. Allday, and D. H. Crawford. 1991. Epstein-Barr virus-associated lymphoproliferative disorders in immunocompromised individuals. Adv. Cancer Res. 57:329-380.
57. Trümper, L. H., G. Brady, A. Bagg, D. Gray, S. L. Loke, H. Griesser, R. Wagman, R. Braziel, R. D. Gascoyne, S. Vicini, N. N. Iscove, J. Cossman, and T. W. Mak. 1993. Single-cell analysis of Hodgkin and Reed-Sternberg cells: molecular heterogeneity of gene expression and p53 mutations. Blood 81:3097-3115.
58. Wang, D., D. Liebowitz, and E. Kieff. 1985. An Epstein-Barr virus membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43:831-840.
59. Wang, F., S.-F. Tsang, M. G. Kurilla, J. I. Cohen, and E. Kieff. 1990. Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J. Virol. 64:3407-3416.
60. Werness, B. A., A. J. Levine, and P. M. Howley. 1990. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:75-79.
61. Wiman, K. G., K. P. Magnusson, T. Ramqvist, and G. Klein. 1991. Mulant p53 detected in a majority of Burkitt lymphoma cell lines by monoclonal antibody PAb240. Oncogene 6:1633-1639.
62. Wu, H., and G. Lozano. 1994. NF-κB activation of p53. J. Biol. Chem. 269:20067-20074.
63. Wu, X., H. Bayle, D. Olson, and A. J. Levine. 1993. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7:1126-1132.
64. Young, L., C. Alfieri, K. Hennessy, H. Evans, C. O'Hara, K. C. Anderson, J. Ritz, R. S. Shapiro, A. Rickinson, E. Kieff, and J. I. Cohen. 1989. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N. Engl. J. Med. 321:1080-1085.
65. Zantema, A., P. I. Schrier, A. Davis-Olivier, T. van Laar, R. T. M. J. Vaessen, and A. J. van der Eb. 1985. Adenovirus serotype determines association and localization of the large E1B tumor antigen with cellular tumor antigen p53 in transformed cells. Mol. Cell. Biol. 5:3084-3091.
66. Zhang, Q., D. Gutsch, and S. Kenney. 1994. Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol. Cell. Biol. 14:1929-1938.